Connect to share and comment

Warfarin to treat irregular heartbeat may up stroke risk at first: study

TORONTO - Some patients with an irregular heartbeat known as atrial fibrillation appear to have almost double the risk of a stroke in the first 30 days after starting treatment with warfarin — even though the anti-clotting drug is prescribed to prevent strokes, a study suggests. Atrial fibrillation can cause blood clots to form in the heart, which can then travel to the brain and result in a blocked artery, leading to an ischemic stroke that destroys nearby neurons.

New Daiichi drug succeeds in major study; set to face rivals

By Bill Berkrot and Ransdell Pierson DALLAS (Reuters) - A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alternatives on the market.

Daiichi blood thinner safer, as effective as warfarin in major study

By Bill Berkrot and Ransdell Pierson DALLAS (Reuters) - A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alternatives on the market.

UK scientists win funding for new kind of anticoagulant drug

LONDON (Reuters) - British scientists have won early financial backing for a new kind of anticoagulant drug they believe may prevent dangerous blood clots without causing bleeding - a previously unachievable goal. Index Ventures, working with GlaxoSmithKline and Johnson & Johnson via an early-stage biotech fund, said on Monday it was investing $11 million in XO1, a new company set up to develop the experimental medicine.

UK's NICE backs wider use of BMS, Pfizer anti-clot drug

LONDON, Jan 23 (Reuters) - Britain's national health costs watchdog has recommended Bristol-Myers Squibb and Pfizer's anti-clotting pill Eliquis for preventing strokes in patients with an irregular heartbeat condition called atrial fibrillation (AF) The draft guidance from the National Institute for Health and Clinical Excellence (NICE) opens up a potential new market for Eliquis, which belongs to a new class of medicines designed to replace the decades-old blood thinner warfarin.
Syndicate content